Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - RAPT Therapeutics

Next Previous
Drug Profile

Research programme: small molecule therapeutics - RAPT Therapeutics

Alternative Names: CCR4 inhibitors - RAPT Therapeutics; GCN2 inhibitors - RAPT Therapeutics; GCN2 program - RAPT Theraperutics; HPK1 Inhibitors - RAPT Therapeutics; MDSC inhibitors - RAPT Theraperutics; Myeloid-derived suppressor cell inhibitors - RAPT Therapeutics; Regulatory T-cell inhibitors - RAPT Therapeutics; USP7 inhibitors - RAPT Therpaeutics

Latest Information Update: 28 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FLX Bio
  • Developer RAPT Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action CCR4 receptor antagonists; EIF2AK4 protein inhibitors; Hematopoietic progenitor kinase 1 inhibitors; Regulatory T lymphocyte inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
  • 14 Mar 2023 Preclinical development in Solid tumours is ongoing in USA (PO)
  • 05 May 2022 Pharmacodynamics data from a preclinical studies in Solid tumours released by RAPT Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top